BDTX
Black Diamond Therapeutics, Inc.
$1.75
-3.85%
$100.3M
No data for this timeframe.
Vol
Market Cap$100.3M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (87%)
Inst. Holders50 funds
Inst. Value$31.0M
Inst. Activity6 buys / 5 sells
Reddit Sentiment50° Neutral
SEC Reports2
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0001701541·Prev Close $1.82
Recent Activity
May 21, 2026
SEC
Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in frontline NSCLC patients with EGFR non-
8-K — Impact 7/10
May 7, 2026
SEC
Black Diamond Therapeutics reported Q1 2026 EPS of -$0.16, beating consensus of -$0.21, with $0 revenue as expected. Net
8-K — Impact 4/10
Mar 20, 2026
Insider
Behbahani Ali was granted 6,919 shares
Director @ $2.15 ($14.9K)
Mar 20, 2026
Insider
Raman Prakash was granted 6,105 shares
Director @ $2.15 ($13.1K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
1,643,747 shares ($3.5M)
Inst.
DIMENSIONAL FUND ADVISORS LP — ADD
1,301,664 shares ($2.8M)
Jun 8, 2026
short_volume
Short Volume: BDTX — 60.7% short (0.3M / 0.6M)
Short: 349,706 | Exempt: 2,248 | TRF Vol: 575,670 | Short Ratio: 60.7% | Off-exchange volume (dark p
May 21, 2026
Press
Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in frontline NSCLC with EGFR non-classical
Impact 8/10
Price Targets
$9.86
+463.3% upside
Strong Buy
Current $1.75
Low $7.00
Median $10.00
High $14.00
7 analysts
$7.00
$14.00
Analyst Ratings
5Strong Buy
8Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 29, 2026 | BTIG | MAINTAIN | Buy → Buy |
| Mar 17, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Jan 16, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.20 ▲ +6.5% | $-0.29 — $-0.13 | -5% YoY | 6 |
| Next Q | $-0.06 ▼ -30.4% | $-0.26 — $0.60 | 60% YoY | 6 |
| Current FY | $-0.63 ▲ +1.1% | $-0.96 — $-0.10 | -222% YoY | 6 |
| Next FY | $-1.16 ▼ -12.6% | $-1.83 — $-0.52 | -84% YoY | 5 |
Latest Reports
BULLISH
Press
8/10
Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in frontline NSCLC with EGFR non-classical
May 21, 2026
BULLISH
8-K
7/10
Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in frontline NSCLC patients with EGFR non-
May 21, 2026
NEUTRAL
8-K
4/10
Black Diamond Therapeutics reported Q1 2026 EPS of -$0.16, beating consensus of -$0.21, with $0 revenue as expected. Net
May 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $3.9M | — |
| RENAISSANCE TECHNOLOGIES LLC | $3.5M | ADD |
| DIMENSIONAL FUND ADVISORS LP | $2.8M | ADD |
| BlackRock, Inc. | $2.4M | — |
| Connor, Clark & Lunn | $2.3M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 20, 2026 | Behbahani Ali | A | $14.9K |
| Mar 20, 2026 | Raman Prakash | A | $13.1K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $31.0M total value (14,580,039 shares) as of 2026-Q1. Top holders: VANGUARD, RENAISSANCE, DIMENSIONAL. Net buying activity: 6 institutions added/increased vs 5 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 1,850,468 | $3.9M | 12.7% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,643,747 | $3.5M | 11.3% | ADD +73.1% |
| 3 | DIMENSIONAL FUND ADVISORS LP | 1,301,664 | $2.8M | 8.9% | ADD +51.9% |
| 4 | BlackRock, Inc. | 1,106,840 | $2.4M | 7.6% | — |
| 5 | Connor, Clark & Lunn Investment Management Ltd. | 1,058,397 | $2.3M | 7.3% | ADD +61.7% |
| 6 | MACKENZIE FINANCIAL CORP | 844,835 | $1.8M | 5.8% | DOUBLED +139.7% |
| 7 | MARSHALL WACE, LLP | 836,266 | $1.8M | 5.7% | ADD +76.1% |
| 8 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 834,570 | $1.8M | 5.7% | DOUBLED +549.2% |
| 9 | GOLDMAN SACHS GROUP INC | 684,418 | $1.5M | 4.7% | — |
| 10 | FMR LLC | 623,827 | $1.3M | 4.3% | ADD +72.7% |
| 11 | BALYASNY ASSET MANAGEMENT L.P. | 510,811 | $1.1M | 3.5% | — |
| 12 | CITADEL ADVISORS LLC | 502,652 | $1.1M | 3.5% | — |
| 13 | D. E. Shaw & Co., Inc. | 363,921 | $775.2K | 2.5% | DOUBLED +356.5% |
| 14 | STIFEL FINANCIAL CORP | 278,645 | $593.5K | 1.9% | — |
| 15 | VANGUARD FIDUCIARY TRUST CO | 259,908 | $553.6K | 1.8% | — |
| 16 | STATE STREET CORP | 213,513 | $454.8K | 1.5% | NEAR_EXIT -75.4% |
| 17 | CANADA PENSION PLAN INVESTMENT BOARD | 211,400 | $450.3K | 1.5% | — |
| 18 | TD ASSET MANAGEMENT INC | 195,930 | $417.3K | 1.3% | — |
| 19 | O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 182,236 | $388.2K | 1.3% | TRIM -48.6% |
| 20 | BANK OF AMERICA CORP /DE/ | 114,143 | $243.1K | 0.8% | DOUBLED +123.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 949,735 | 1,643,747 | +73.1% | $3.5M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 857,015 | 1,301,664 | +51.9% | $2.8M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | 654,699 | 1,058,397 | +61.7% | $2.3M | 2026-Q1 |
| MACKENZIE FINANCIAL CORP | DOUBLED | 352,454 | 844,835 | +139.7% | $1.8M | 2026-Q1 |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | TRIM | 354,454 | 182,236 | -48.6% | $388.2K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 51,103 | 114,143 | +123.4% | $243.1K | 2026-Q1 |
| Point72 Asset Management, L.P. | TRIM | 196,741 | 100,985 | -48.7% | $215.1K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | TRIM | 138,900 | 62,800 | -54.8% | $133.8K | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | ADD | 12,850 | 17,150 | +33.5% | $36.5K | 2026-Q1 |
| CWM, LLC | NEAR_EXIT | 365 | 74 | -79.7% | $158.00 | 2026-Q1 |
| HRT FINANCIAL LP | TRIM | 26,351 | 12,022 | -54.4% | $25.00 | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 599,400 | 949,735 | +58.4% | $2.3M | 2025-Q4 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 455,870 | 857,015 | +88.0% | $2.1M | 2025-Q4 |
| D. E. Shaw & Co., Inc. | DOUBLED | 143,643 | 655,772 | +356.5% | $1.6M | 2025-Q4 |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | 131,635 | 654,699 | +397.4% | $1.6M | 2025-Q4 |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | DOUBLED | 142,439 | 354,454 | +148.8% | $861.3K | 2025-Q4 |
| OMERS ADMINISTRATION Corp | DOUBLED | 11,000 | 138,900 | +1162.7% | $337.5K | 2025-Q4 |
| Invesco Ltd. | ADD | 95,344 | 131,438 | +37.9% | $319.4K | 2025-Q4 |
| MORGAN STANLEY | ADD | 69,138 | 95,149 | +37.6% | $231.2K | 2025-Q4 |
| GROUP ONE TRADING LLC | TRIM | 4,385 | 1,618 | -63.1% | $3.9K | 2025-Q4 |
| CWM, LLC | NEAR_EXIT | 1,470 | 365 | -75.2% | $1.00 | 2025-Q4 |
| MARSHALL WACE, LLP | ADD | 737,875 | 1,299,208 | +76.1% | $4.9M | 2025-Q3 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | 138,144 | 896,853 | +549.2% | $3.4M | 2025-Q3 |
| UBS Group AG | DOUBLED | 313,700 | 628,416 | +100.3% | $2.4M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 167,100 | 599,400 | +258.7% | $2.3M | 2025-Q3 |
2 unique insiders with 2 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 20, 2026 | Behbahani Ali | Director | AWARD | 6,919 | $2.15 | $14.9K |
| Mar 20, 2026 | Raman Prakash | Director | AWARD | 6,105 | $2.15 | $13.1K |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.5/10.
BULLISH
8/10
Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in frontline NSCLC wit
May 21, 2026
BULLISH
7/10
Black Diamond Therapeutics announced upcoming presentations of Phase 2 data for silevertinib in non-
Apr 21, 2026
MIXED
6/10
Black Diamond Therapeutics reported financial results for Q4 and full year 2025, highlighted by a si
Mar 16, 2026
Current analyst consensus: Strong Buy (87% buy). Based on 15 analysts: 5 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$9.86 mean target
+463.3% upside
Strong Buy (1.44)
$7.00 Low
$14.00 High
| Metric | Value |
|---|---|
| Current Price | $1.75 |
| Target Low | $7.00 |
| Target Mean | $9.86 |
| Target Median | $10.00 |
| Target High | $14.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.44) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.20 | $-0.29 | $-0.13 | -5.3% | +6.5% | 2↑ 1↓ | $0.0B | 0.0% | 6 |
| Next Q 2026-09-30 |
$-0.06 | $-0.26 | $0.60 | 60.0% | -30.4% | 2↑ 1↓ | $0.0B | 0.0% | 6 |
| Current FY 2026-12-31 |
$-0.63 | $-0.96 | $-0.10 | -222.4% | +1.1% | 2↑ 3↓ | $0.0B | -92.1% | 6 |
| Next FY 2027-12-31 |
$-1.16 | $-1.83 | $-0.52 | -84.0% | -12.6% | 2↑ 2↓ | $0.0B | -100.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.200 | |
| 7d ago | $-0.193 | -0.007 |
| 30d ago | $-0.214 | +0.014 |
| 60d ago | $-0.214 | +0.014 |
| 90d ago | $-0.204 | +0.004 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 29, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Jan 16, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 8 | 2 | 0 | 0 | 87% | |
| May 1, 2026 | 5 | 8 | 2 | 0 | 0 | 87% | |
| Apr 1, 2026 | 5 | 8 | 2 | 0 | 0 | 87% | |
| Mar 1, 2026 | 5 | 8 | 2 | 0 | 0 | 87% | |
| Feb 1, 2026 | 5 | 8 | 2 | 0 | 0 | 87% | |
| Jan 1, 2026 | 5 | 8 | 2 | 0 | 0 | 87% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
4 mentions
2 bullish
2 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 29, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 29, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
WHAT ARE THE BIGGEST LOSERS TODAY AND WHY
▲ 1
💬 1
⚡ 0.5
Jun 8, 2026
short_volume
Short Volume: BDTX — 60.7% short (0.3M / 0.6M)
Short: 349,706 | Exempt: 2,248 | TRF Vol: 575,670 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
May 22, 2026
other
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
<p align="left">CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ZQbin8Z_Gn0aJZPccENEsfhOqYolF
May 22, 2026
short_volume
Short Volume: BDTX — 55.8% short (2.3M / 4.1M)
Short: 2,280,816 | Exempt: 160,535 | TRF Vol: 4,089,098 | Short Ratio: 55.8% | Off-exchange volume (dark pool + OTC)
May 21, 2026
fda
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
<p>CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing
May 19, 2026
short_volume
Short Volume: BDTX — 57.0% short (0.4M / 0.7M)
Short: 382,496 | Exempt: 0 | TRF Vol: 670,568 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
BDTX Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
BDTX Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
earnings
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="justify">CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology com
May 7, 2026
short_volume
Short Volume: BDTX — 58.5% short (0.6M / 1.0M)
Short: 588,803 | Exempt: 56,170 | TRF Vol: 1,006,476 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
fda
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
<p>CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developin
Mar 18, 2026
earnings_calendar
BDTX Q4 2025 Earnings After Market Close — 2026-03-18
Mar 16, 2026
earnings
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
<p align="left">CAMBRIDGE, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology comp
Mar 4, 2026
earnings_calendar
BDTX Q4 2025 Earnings After Market Close — 2026-03-04
Mar 2, 2026
other
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
<p align="justify">CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=gLf3gt0efFvxAFsm77WJ2SlS